{"id":4992,"date":"2026-08-03T15:50:51","date_gmt":"2026-08-03T15:50:51","guid":{"rendered":"https:\/\/futureknowledge.in\/?p=4992"},"modified":"2026-08-03T15:50:51","modified_gmt":"2026-08-03T15:50:51","slug":"astrazeneca-shares-plunge-over-talks-with-us-cancer-drug-firm-on-400bn-merger","status":"publish","type":"post","link":"https:\/\/futureknowledge.in\/?p=4992","title":{"rendered":"AstraZeneca shares plunge over talks with US cancer drug firm on $400bn merger"},"content":{"rendered":"<p>Bristol Myers Squibb tie-up would create world\u2019s fourth largest drugmaker but analysts question rationale for deal<\/p>\n<p>More than \u00a315bn was wiped off the value of Britain\u2019s biggest drugmaker, AstraZeneca, on Monday after a report that it was in discussions to take over its US rival Bristol Myers Squibb in a deal that would create a near $400bn (\u00a3300bn) pharmaceutical group.<\/p>\n<p>AstraZeneca, run by Pascal Soriot, its longtime chief executive, is the second biggest listed company in the UK, with a market value of nearly \u00a3196bn before the news broke. BMS, headquartered in Princeton, New Jersey, and known for its cancer treatments, is worth $133bn.<\/p>\n<p> <a href=\"https:\/\/www.theguardian.com\/business\/2026\/aug\/03\/astrazeneca-talks-bristol-myers-squibb-merger-pharmaceuticals\">Continue reading&#8230;<\/a><\/p>\n<p><em>Source: <a href='https:\/\/www.theguardian.com\/business\/2026\/aug\/03\/astrazeneca-talks-bristol-myers-squibb-merger-pharmaceuticals' target='_blank'>Read the original article on www.theguardian.com<\/a><\/em><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Bristol Myers Squibb tie-up would create world\u2019s fourth largest drugmaker but analysts question rationale for deal More than \u00a315bn was wiped off the value of Britain\u2019s biggest drugmaker, AstraZeneca, on Monday after a report that it was in discussions to take over its US rival Bristol Myers Squibb in a deal that would create a [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":4993,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[2,4],"tags":[],"class_list":["post-4992","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-business","category-important"],"_links":{"self":[{"href":"https:\/\/futureknowledge.in\/index.php?rest_route=\/wp\/v2\/posts\/4992","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/futureknowledge.in\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/futureknowledge.in\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/futureknowledge.in\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/futureknowledge.in\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=4992"}],"version-history":[{"count":0,"href":"https:\/\/futureknowledge.in\/index.php?rest_route=\/wp\/v2\/posts\/4992\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/futureknowledge.in\/index.php?rest_route=\/wp\/v2\/media\/4993"}],"wp:attachment":[{"href":"https:\/\/futureknowledge.in\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=4992"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/futureknowledge.in\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=4992"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/futureknowledge.in\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=4992"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}